Molecular Cancer Research

Dr. Jessica Clague DeHart of Claremont Graduate University and LYTE Foundation to receive data and findings of the important Health of Women (HOW) Study® and the Metastatic Breast Cancer Collateral Damage (MBCCD) Project

Retrieved on: 
Wednesday, November 29, 2023
Diet, Woman, Associate, Research, Breast cancer, Breast Cancer Research, HOW, Exercise, Disease, LOS, Collateral damage, Claremont Graduate University, MBC, Quality of life, Molecular Cancer Research, Birth control

LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The 6-year Health of Women (HOW) Study was a first-of-its kind international online study to better understand breast cancer and its underlying cause. The HOW Study® asked health-related questions on topics like family history, reproductive health, diet, and exercise. Over the course of the study, more than 65,000 women participated to help identify how family history, reproductive health, diet and exercise contribute to the cause of breast cancer. Preliminary results from the HOW Study revealed a critical need to address issues often overlooked among those living with metastatic breast cancer (MBC). While industry partners develop treatments that will keep people alive longer, the MBCCD project set out to help them live better. This project documented a full range of collateral damage experienced by those living with MBC and is currently developing a set of recommendations aimed at improving quality of life.

Key Points: 
  • Dr. Susan Love Foundation to transfer data and findings to continue the work on breast cancer research and other women's health issues.
  • Over the course of the study, more than 65,000 women participated to help identify how family history, reproductive health, diet and exercise contribute to the cause of breast cancer.
  • Preliminary results from the HOW Study revealed a critical need to address issues often overlooked among those living with metastatic breast cancer (MBC).
  • Dr. Jessica Clague DeHart is a molecular cancer epidemiologist, Associate Professor at Claremont Graduate University, and the CEO/Founder of LYTE Foundation.

DR. CAROLYN WONG SIMPKINS NAMED PRESIDENT OF ZYNX, A HEARST HEALTH COMPANY

Retrieved on: 
Monday, November 27, 2023
Johns Hopkins, Duke University, Internal medicine, Medical journal, Stanford University, Health, Pharmacology, BMJ, Molecular Cancer Research, Biology, Prisma Health, Dentistry, Zynx Health

NEW YORK, Nov. 27, 2023 /PRNewswire/ -- Hearst announced today that Carolyn Wong Simpkins, M.D., Ph.D., has been named president of its Zynx Health business unit, effective immediately.

Key Points: 
  • NEW YORK, Nov. 27, 2023 /PRNewswire/ -- Hearst announced today that Carolyn Wong Simpkins, M.D., Ph.D., has been named president of its Zynx Health business unit, effective immediately.
  • The announcement was made by Steven R. Swartz, president and chief executive officer of Hearst; Gregory Dorn, M.D., president of Hearst Health; and Charles Tuchinda, M.D., executive vice president of Hearst Health.
  • She succeeds Tuchinda, who has served as president of Zynx since 2019 in addition to his Hearst Health group leadership responsibilities.
  • She has served as a medical director at Greenville Health System, focusing on an interdisciplinary cardiovascular risk reduction program and women's health.

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Bispecific monoclonal antibody, Cycle, Patient, NRAS, FDA, Molecular Cancer Research, Research, Research and development, New Drug Application, IND, American Association for Cancer Research, CD3, PDUFA, Multiple myeloma, Amgen, TEAD, Biotechnology, Regeneron Pharmaceuticals, MAPK, Prescription Drug User Fee Act, Plantar fibromatosis, G&A, European Medicines Agency, Panitumumab, R, RAF, Solar cycle 10, MEK, Growth, Common, Annual general meeting, EMA, Solar cycle 2, NDA, Cancer, Therapy, Solar cycle 24, BCMA, Administration, BeiGene, EGFR, Pharmaceutical industry, Medical imaging

STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported third quarter financial results for the period ended September 30, 2023 and provided an update on recent business highlights.

Key Points: 
  • – PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 –
    STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported third quarter financial results for the period ended September 30, 2023 and provided an update on recent business highlights.
  • SpringWorks expects to file a Marketing Authorisation Application for nirogacestat with the European Medicines Agency (EMA) in the first half of 2024.
  • SpringWorks plans to file an IND for SW-682, the Company's TEAD inhibitor development candidate, in the fourth quarter of 2023.
  • Net Loss Attributable to Common Stockholders: SpringWorks reported a net loss of $79.4 million, or $1.27 per share, for the third quarter of 2023.

Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum

Retrieved on: 
Friday, September 29, 2023
ARG1, Sarcoidosis, Saskatchewan River Sturgeon Management Board, POC, Partnership, CET, American Association for Cancer Research, Financial and social rankings of sovereign states in Europe, Food, Proof of concept, Acceleration, Food and Drug Administration, Clinical trial, Public, Cancer, RNA, Research, Messenger, Strategy, EMA, Trust, Patient, ARG2, European, PLN, MOC, FDA, Therapy, IND, Molecular Cancer Research, Phase, Safety, Pharmaceutical industry, Cryptocurrency, Vaccine, Fine chemical

Marcin Szumowski, CEO and President of the Management Board of Molecure said “Many events of this year were crucial for further development of Molecure.

Key Points: 
  • Marcin Szumowski, CEO and President of the Management Board of Molecure said “Many events of this year were crucial for further development of Molecure.
  • In June, we announced the updated strategy for 2023-2025, the implementation of which will enable us to continue building the company's value.
  • Bringing two of our most advanced programs to patients opened a new and exciting chapter for Molecure.
  • Molecure has signed an agreement with Simbec-Orion, a leading global Clinical Research Organisation which will conduct the clinical trial on behalf of Molecure.

CHU Bordeaux is live on SOPHiA GENETICS

Retrieved on: 
Wednesday, August 30, 2023
Database, DNA, HRD, NGS, Cancer, Breast, Research, Prostate, Genome, Molecular Cancer Research, Sophia, Sophia Genetics, Platform, Machine learning, GENETICS, Medicine, Artificial intelligence, Vaccine, HRR

BOSTON and ROLLE, Switzerland, Aug. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization. The hospital will be using the SOPHiA GENETICS technology to help advance its research on homologous recombination repair (HRR) mutated cancers.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Aug. 30, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that CHU Bordeaux, a full-service hospital servicing the population of Bordeaux and the surrounding area, has completed implementation of the SOPHiA DDM™ Platform into its organization.
  • The SOPHiA DDM™ Platform provides reliable and fast HRD results that can help guide the team at CHU Bordeaux in generating data-driven insights.
  • The SOPHiA DDM™ Platform will help CHU Bordeaux create a more efficient bioinformatics workflow for accuracy and simplification where possible when analyzing NGS data.
  • Additionally, with the SOPHiA DDM™ Platform technology CHU Bordeaux will be able to create an in-house database from genomics profiles its researchers analyze.

Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response

Retrieved on: 
Tuesday, April 25, 2023
Science, Health, Oncology, Research, ICI, IO, Survival, Clinical trial, Cancer, Multimedia, Biomarker, Immunotherapy, Doctor of Philosophy, Molecular Cancer Research, GH, Helmy Eltoukhy, Patient, Tumor microenvironment, Medical imaging

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, today announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, today announced a research collaboration agreement to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across more than 14 different types of cancer.
  • The testing, which will be conducted with GuardantINFINITY, will provide a multi-dimensional analysis of each patient’s tumor response based on both genomic and epigenomic profiling.
  • The study will use blood samples drawn at multiple points during the treatment regimen and will assess the connection between the presence of specific cancer biomarkers and real-world clinical outcomes, including survival and immune-related adverse events.
  • “The collaborative study with PICI is an excellent opportunity for us to explore the value of genomic and epigenomic tumor profiling in real-world immuno-oncology therapy settings,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.

MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models

Retrieved on: 
Tuesday, April 18, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, AACR, Telomere, American Association for Cancer Research, Hepatocellular carcinoma, DC, Clinical trial, Cancer, Liver cancer, HMGB1, Therapy, B cell, NYSE, HCC, Molecular Cancer Research, Pharmaceutical industry, Vaccine

The preclinical study, entitled “Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma,” showed highly potent anticancer activity of THIO in multiple HCC preclinical models.

Key Points: 
  • The preclinical study, entitled “Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma,” showed highly potent anticancer activity of THIO in multiple HCC preclinical models.
  • The study revealed the anti-tumor immune response role of THIO as a telomerase-dependent telomere targeting therapeutic in HCC models.
  • THIO induces telomere damage and activates the cGAS-STING pathway, which is a major intracellular signaling pathway that plays a role in innate immune responses.
  • THIO enhances the cross-priming capacity of dendritic cells (DCs), which are antigen presenting cells of the adaptive immune system and activates tumor specific T cells.

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Retrieved on: 
Sunday, April 16, 2023
Molecule, Extremities, Human, AACR, University, NF2, American Association for Cancer Research, Urine, Alanine transaminase, Neoplasm, YAP, Neurofibromatosis, Trial of the century, Mesothelioma, MD Anderson Cancer Center, TEAD, Plasma, Sarcoma, Merlin, Patient, Swelling, SAN, Article, Albuminuria, Nausea, Biology, Pulmonary toxicity, Therapy, Hippopotamus, News, Molecular Cancer Research, Fatigue, Pharmaceutical industry, Medical imaging

SAN MATEO, Calif., April 16, 2023 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. Results from the company's Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, showed the compound to be well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. These findings were presented by Timothy A. Yap, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, during an oral plenary session at the conference. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • The AACR conference is being held April 14-19, 2023, in Orlando, Florida.
  • Tumor response was observed in patients with mesothelioma with and without NF2 mutations and other solid tumors with NF2 mutations.
  • Because mesothelioma patients often have NF2 mutations or loss of Merlin it was an a priori indication of interest.
  • "Preclinical data suggested that blocking the YAP-TEAD interaction could shrink tumors, and these clinical data validate that approach.

Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS

Retrieved on: 
Tuesday, April 4, 2023
Software, Research, Oncology, Data Management, Technology, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, DNA, Medicine, HRR, HRD, Deep learning, Breast, Prostate, Molecular Cancer Research, Genome, Sophia, Sophia Genetics, Patient, Tel Aviv Sourasky Medical Center, Laboratory, Medical Center, Algorithm, GENETICS, Cancer, Ezra Ichilov, Genetic testing, Ovarian cancer, PARP, Medical imaging, Pharmaceutical industry, Antibiotics

By implementing SOPHiA DDMTM HRD Solution, Tel Aviv Sourasky Medical Center (Ichilov) will have the opportunity to identify larger populations of individuals with HRD-positive cancer who may benefit from treatment with PARP inhibitors (PARPi).

Key Points: 
  • By implementing SOPHiA DDMTM HRD Solution, Tel Aviv Sourasky Medical Center (Ichilov) will have the opportunity to identify larger populations of individuals with HRD-positive cancer who may benefit from treatment with PARP inhibitors (PARPi).
  • “The implementation of methods able to detect HRD is crucial for identifying patients who could benefit from treatment with PARPi,” said Dr. Ariel Erental, Tel Aviv Sourasky Medical Center.
  • “The SOPHiA DDMTM HRD Solution will help to inform data-driven decisions that advance the clinical research at Tel Aviv Sourasky Medical Center into HRD-associated cancers.”
    SOPHiA DDMTM HRD Solution enables laboratories and healthcare institutions to identify HRR mutations and measure genomic instability via a decentralized approach.
  • “By implementing SOPHiA DDMTM HRD Solution, Tel Aviv Sourasky Medical Center will have access to high analytical performance and streamlined bioinformatics workflows, making it more efficient to detect HRD status in advanced ovarian cancer and other relevant cancers.”
    In addition to supporting Tel Aviv Sourasky Medical Center in its work to detect HRD status in select cancers, the powerful analytics of SOPHiA DDMTM HRD Solution will help the Medical Center maximize in-house genomic insights to help advance its clinical research capabilities.

Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics

Retrieved on: 
Wednesday, April 12, 2023
DNA, HGF, Mesenchymal–epithelial transition, American Association for Cancer Research, HGFR, Fetus, Epithelium, Carcinoma, Head, Lung cancer, DNA repair, Patient, Immunoglobulin G, Melanoma, MET, United Kingdom, ADC, Growth, Neoplasm, Therapy, Molecular Cancer Research, Pharmaceutical industry, Vaccine

NIJMEGEN, Netherlands, April 12, 2023 /PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that Molecular Cancer Therapeutics (an American Association for Cancer Research journal) has published encouraging preclinical data on its investigational, next generation antibody-drug conjugate (ADC) BYON3521.

Key Points: 
  • NIJMEGEN, Netherlands, April 12, 2023 /PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that Molecular Cancer Therapeutics (an American Association for Cancer Research journal) has published encouraging preclinical data on its investigational, next generation antibody-drug conjugate (ADC) BYON3521.
  • The article, "Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate," suggests that BYON3521 has an encouraging safety/efficacy window with potential for clinical benefit in patients.
  • The data from in vitro and in vivo studies showed that BYON3521 potently and selectively kills tumor cells expressing c-MET, even at low c-MET-expressing levels.
  • The antibody part of BYON3521 binds to c-MET on the surface of the cancer cell and the ADC is internalized.